FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
Posted on 18 Nov 2026
Influenza and respiratory syncytial virus (RSV) often circulate during the same season and cause overlapping symptoms, making accurate differentiation important for clinical management. Seasonal testing surges can also strain laboratory capacity. A newly cleared molecular test aims to streamline diagnosis by detecting and differentiating influenza A, influenza B, and RSV from anterior nasal swabs in a single run.
Molecular Designs (Birmingham, AL, USA) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SimplicityDx Panel FluA/FluB/RSV under K262789, marking the company’s first FDA-cleared test. The assay is designed to qualitatively detect and differentiate influenza A, influenza B, and respiratory syncytial virus (RSV) RNA in anterior nasal swab specimens from patients with signs and symptoms of respiratory tract infection.

The SimplicityDx Panel FluA/FluB/RSV uses multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) technology to detect all three respiratory viruses, along with an internal control, in a single run. Designed for use with Molecular Designs’ Simplicity Dx Extraction products, the panel features a breakaway format that allows laboratories to use only the tests needed for each run. This approach minimizes pipetting steps while supporting batch processing during periods of high testing demand.
The assay is intended to aid differential diagnosis when used alongside clinical, epidemiological, and other laboratory findings. It is available for prescription use only and is restricted to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
“This is a defining moment for Molecular Designs. Earning FDA clearance requires rigorous manufacturing, robust quality systems and scientific discipline, and our team built all three. With respiratory season underway, we're ready to support labs with a cleared, practical way to test for flu A, flu B and RSV in a single run,” said Michael Clark, CEO of Molecular Designs.
“Our goal was never just to add another respiratory test. We set out to design one around how clinical labs actually work, with quality and efficiency as priorities from the start. Every choice, from the assay format to the run controls, came from working alongside lab teams and listening to what they need day to day,” said Dr. Greer Massey, Chief Scientific Officer of Molecular Designs.
Related Links
Molecular Designs







.jpg)